Integrated BioPharma (OTCMKTS:INBP – Get Free Report) and Mainz Biomed (NASDAQ:MYNZ – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, valuation, profitability and dividends.
Profitability
This table compares Integrated BioPharma and Mainz Biomed’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Integrated BioPharma | -0.23% | -0.62% | -0.44% |
Mainz Biomed | -2,934.82% | -488.05% | -145.77% |
Valuation & Earnings
This table compares Integrated BioPharma and Mainz Biomed’s top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Integrated BioPharma | $50.67 million | 0.12 | -$30,000.00 | N/A | N/A |
Mainz Biomed | $900,000.00 | N/A | -$26.30 million | ($1.64) | -0.21 |
Risk & Volatility
Integrated BioPharma has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Comparatively, Mainz Biomed has a beta of 0.15, suggesting that its stock price is 85% less volatile than the S&P 500.
Insider and Institutional Ownership
25.3% of Integrated BioPharma shares are held by institutional investors. 45.6% of Integrated BioPharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Analyst Ratings
This is a summary of recent recommendations and price targets for Integrated BioPharma and Mainz Biomed, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Integrated BioPharma | 0 | 0 | 0 | 0 | N/A |
Mainz Biomed | 0 | 1 | 1 | 0 | 2.50 |
Mainz Biomed has a consensus target price of $6.00, indicating a potential upside of 1,638.12%. Given Mainz Biomed’s higher possible upside, analysts clearly believe Mainz Biomed is more favorable than Integrated BioPharma.
Summary
Integrated BioPharma beats Mainz Biomed on 8 of the 10 factors compared between the two stocks.
About Integrated BioPharma
Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical Businesses segment distributes healthful nutritional products for sale through mass market, grocery, drug, and vitamin retailers under the Peaceful Sleep and Wheatgrass brands, as well as other branded proprietary nutraceutical products. This segment also sells private label vitamin and nutritional supplement products through the Internet; provides warehousing and fulfilment services; and distributes fine natural botanicals, including multi minerals, as well as raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.
About Mainz Biomed
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.
Receive News & Ratings for Integrated BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integrated BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.